Document is current

Article History

Received: 23 June 2024

Accepted: 3 April 2025

First Online: 11 April 2025

Declarations

:

: This study was approved by the Institutional Review Board of Kumamoto University Hospital (No. 2226) and was conducted in accordance with the principles of the Declaration of Helsinki.

: The authors declare no competing interests.

: HT has received honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Novartis, SymBio Pharmaceuticals Limited, Takeda Pharmaceutical, Meiji Seika Pharma, and Abbvie Inc., and patents and royalties from mesoblasts. KN has received Meiji Seika, Janssen, Chugai, Bristol Myers Squibb, Kyowa Kirin, Abbvie, Daiichi Sankyo, Ohara, and research funding from Kyowa Kirin, Chugai. DM has received Research funding from Ono, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Zenyaku, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Otsuka, Taiho, Pfizer, Astellas, and honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai, Kyowa Kirin, MSD, Zenyaku, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis. The rest of the authors declare no conflicts of interest.